Spero Therapeutics, Inc.
SPRO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.27 | 0.02 | -0.03 |
| FCF Yield | 16.47% | -10.89% | -10.04% | -42.04% |
| EV / EBITDA | -7.65 | -57.14 | 0.35 | -0.34 |
| Quality | ||||
| ROIC | -18.66% | -4.99% | -29.26% | -34.85% |
| Gross Margin | 0.00% | 100.00% | -131.63% | -529.05% |
| Cash Conversion Ratio | -2.36 | 10.41 | 0.29 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -22.42% | -4.01% | -4.01% | -4.05% |
| Free Cash Flow Growth | 198.47% | -342.10% | 82.90% | -283.35% |
| Safety | ||||
| Net Debt / EBITDA | 5.72 | 11.68 | 3.09 | 2.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 40.67 | 186.47 | 360.32 | 306.99 |